Next-generation sequencing (NGS) in 936 patients (pts) with advanced cancers to prospectively guide clinical trial selection: The Sarah Cannon Research Institute (SCRI) experience.-Reference-Cited by-同舟云学术

Next-generation sequencing (NGS) in 936 patients (pts) with advanced cancers to prospectively guide clinical trial selection: The Sarah Cannon Research Institute (SCRI) experience.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:2534-2534
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Bauer Todd Michael¹,Spigel David R.¹,Ma Zeqiang²,Arkenau Hendrik-Tobias³,Chandra Pranil⁴,Prescott James⁴,Lane Cassie M²,Jones Suzanne Fields²,Yardley Denise A.¹,Bendell Johanna C.¹,Burris Howard A.¹,Infante Jeffrey R.⁵

Affiliation:

1. Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

2. Sarah Cannon Research Institute, Nashville, TN

3. Sarah Cannon Research United Kingdom, London, United Kingdom

4. PathGroup, Nashville, TN

5. Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.2534

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospective analysis of 895 patients on a UK Genomics Review Board;ESMO Open;2019

2. C-MET inhibitors for advanced non-small cell lung cancer;Expert Opinion on Investigational Drugs;2018-04-03

3. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale;Molecular Cancer Therapeutics;2017-04

4. New Targets in Non–Small Cell Lung Cancer;Hematology/Oncology Clinics of North America;2017-02

5. Trials and Tribulations of EGFR and MET Inhibitor Combination Therapy in NSCLC;Journal of Thoracic Oncology;2017-01